GLP-1 drops, patches, and nasal sprays: FDA status and verification

As of September 7, 2026, the cited Wegovy and Foundayo FDA records document specific approved weight-management tablets and an injection; they do not establish approval for sublingual drops, transdermal patches, nasal sprays, troches, or dissolving films. A different route is a different drug product and cannot borrow another product’s approval or trial results. Verify ingredient, formulation, route, manufacturer or compounder, prescription or order, label, evidence, and lawful supply.¹²³⁴

The statement is date-bounded because approvals can change. It is also product-bounded: “GLP-1” names a drug mechanism or class, not a finished medicine.

Route is part of the product identity

Wegovy’s current FDA-submitted labeling identifies semaglutide tablets and injection with formulation-specific administration and indications.³ Foundayo is a separately approved oral finished drug containing orforglipron with its own label.⁴ Neither record authorizes a seller to make semaglutide drops or a “GLP-1 patch” by analogy.

Why changing route changes the evidence question

A peptide, small molecule, salt, solvent and delivery system can behave differently when swallowed, held under the tongue, sprayed into the nose, placed on skin or injected. Absorption, bioavailability, stability, local exposure, device or adhesive performance, dosing precision, interactions and storage can all change.

Ask an alternative-route seller for:

• exact active ingredient and chemical form;
• concentration and complete inactive ingredients;
• finished dosage form and route;
• absorption and pharmacokinetic evidence for that formulation;
• dose-delivery accuracy and uniformity;
• stability and container-closure data;
• clinical evidence for the same product, route, population and endpoint;
• adverse-event and interaction plan; and
• basis for every claim of equivalence, convenience or fewer effects.

A study of injected semaglutide does not establish that a compounded sublingual product reaches comparable exposure. A trial of an approved tablet does not validate a patch with a different ingredient.

Compounding needs a real statutory and pharmacy chain

FDA states that compounded drugs are not FDA approved and are not reviewed before marketing for safety, effectiveness or quality in the same way as approved drugs.¹⁵ FDA’s April 2026 summary states that section 503A applies to compounding for an individual patient based on receipt of a prescription; section 503B follows a separate outsourcing-facility framework.² “Needle-free preference” in an ad is not by itself proof that either path applies.

FDA’s April 2026 explanation notes that route matters within its policy for deciding whether a compounded product is essentially a copy of a commercially available drug.² That policy language should not be reversed into “changing the route always makes compounding lawful.” All applicable conditions still matter.

Use the compounded GLP-1 guide to verify shortage status or another applicable basis, the 503A or 503B path, ingredient form, compounder, label, dosing and adverse-event reports. Use the telehealth verification guide when the offer arrives through an online program.

Decode “sublingual” and “oral” precisely

A product held under the tongue or against the cheek is not automatically the same as an FDA-approved tablet swallowed under labeled instructions. “Oral” can describe several routes in marketing; record whether the product is swallowed, dissolved, held buccally or sublingually, or used as a spray.

Then identify dose unit: milligrams per tablet, milligrams per milliliter, drops per dose, spray actuations, film or troche strength. Do not convert between routes or products from the number alone. This article does not provide dosing or switching instructions.

Preserve what is actually dispensed

The prescription, checkout page and delivered label should agree on prescriber, patient, pharmacy, ingredient, form, concentration, route, quantity, instructions, lot and beyond-use date. FDA reports concerns about fraudulent compounded labels, nonexistent pharmacies, storage, dosing errors and unapproved products.¹ Verify the pharmacy independently rather than using the label’s phone number as the only source.

1. Capture the exact offer. Save the date, seller, claims, ingredient, route, dosage form, price, subscription terms and promised source.
2. Search approved products. Match the finished product—not only the molecule—to the current application and route-specific labeling.
3. Verify any compounded path. For 503A, identify the licensed pharmacist or physician and individual-patient prescription basis; for 503B, identify the registered outsourcing facility and applicable order record. Preserve the formula, label, testing and lawful basis.
4. Demand route-specific evidence. Look for pharmacokinetics, dose uniformity, stability, clinical outcomes and harms for the same formulation and route.
5. Reconcile delivery. Compare prescription, pharmacy record, package, lot, storage, instructions and received dosage form before attributing any approval status.

The decisive question is: “What exact FDA record or lawful compounding basis supports this finished ingredient, dosage form and route—and what route-specific evidence supports the claims?”